Lipids
Updated Guideline | Cardiovascular disease risk assessment and reduction, including lipid modification
13 Feb, 2023 | 12:47h | UTCRelated Guidelines:
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Abbreviated lipid guidelines for clinical practice
13 Feb, 2023 | 12:46h | UTCOriginal Guidelines
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Related:
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation
Lipid‐lowering trials are not representative of patients managed in clinical practice: a systematic review and meta‐analysis of exclusion criteria
2 Feb, 2023 | 14:52h | UTC
M-A | Association between autism spectrum disorders and cardiometabolic diseases
1 Feb, 2023 | 13:11h | UTCAssociation Between Autism Spectrum Disorders and Cardiometabolic Diseases: A Systematic Review and Meta-analysis – JAMA Pediatrics (free for a limited period)
Editorial: Autism, Physical Health Conditions, and a Need for Reform – JAMA Pediatrics (free for a limited period)
Commentary on Twitter
Study results suggest that having autism may be associated with a higher risk of developing diabetes, dyslipidemia, and heart disease. https://t.co/T19VAQxdjf
— JAMA Pediatrics (@JAMAPediatrics) January 30, 2023
Perspective | The case of statins, diabetes, and bias in observational studies
24 Jan, 2023 | 14:35h | UTCThe Case of Statins, Diabetes, and Bias in Observational Studies – Sensible Medicine
Restoring mortality data in the FOURIER trial of evolocumab in patients with CVD: a reanalysis based on regulatory data
10 Jan, 2023 | 14:49h | UTCCommentaries:
Yet Another Story on Re-Analyzing a Major Trial – Sensible Medicine
Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees – TCTMD
The year in cardiovascular medicine 2022: the top 10 papers in dyslipidemias
9 Jan, 2023 | 14:26h | UTC
Commentary on Twitter
The Year in Cardiovascular Medicine 2022 series: the Top 10 papers in Dyslipidaemia https://t.co/jpkqgt4Hf1 @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #dyslipidemia pic.twitter.com/UBfKy45mAu
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2023
Cohort Study | Association of the triglyceride glucose index as a measure of insulin resistance with mortality and CVD
9 Jan, 2023 | 13:42h | UTCInvited Commentary: The triglyceride glucose index and cardiovascular disease outcomes – The Lancet Health Longevity
Cohort Study | Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood.
9 Dec, 2022 | 13:11h | UTCLipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood – Circulation
Commentary: Lp(a) in Youth and Risk of ASCVD Outcomes in Adulthood – American College of Cardiology
Commentary on Twitter
#OriginalResearch Childhood Lp(a) levels are associated with significantly increased risk of develping ASCVD as adults @UTUpophealth @olraita #AHAJournals https://t.co/oqHv19QU6l pic.twitter.com/ByZmtRrXqy
— Circulation (@CircAHA) November 30, 2022
Podcast | Advanced lipidology.
30 Nov, 2022 | 13:32h | UTC#361 Advanced Lipidology – The Curbsiders
RCT | Vitamin D fails to prevent statin-associated muscle symptoms among new statin users.
25 Nov, 2022 | 12:40h | UTCStatin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo – JAMA Cardiology (free for a limited period)
Commentary: Vitamin D fails to reduce statin-associated muscle pain – Northwestern University
Commentary on Twitter
Vitamin D supplementation did not prevent statin-associated muscle symptoms or reduce statin discontinuation among new statin users in the randomized VITAL trial. https://t.co/wNZoeJ8PZf
— JAMA Cardiology (@JAMACardio) November 23, 2022
Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.
23 Nov, 2022 | 14:02h | UTCNews Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
17 Nov, 2022 | 12:17h | UTCCommentary: Inclisiran and Cardiovascular Events – American College of Cardiology
Commentary on Twitter
https://twitter.com/ESC_Journals/status/1592113799481692162
RCT | Comparative effects of low-dose rosuvastatin vs. dietary supplements on lipids and inflammatory biomarkers.
16 Nov, 2022 | 13:41h | UTCNews Release: 6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins – American Heart Association
Commentaries:
Study – For Lowering Cholesterol, Statins Work, Supplements Don’t – Science-Based Medicine
Statins vs. supplements: New study finds one is ‘vastly superior’ to cut cholesterol – NPR
Canadian guideline for the prevention and management of cardiovascular disease in primary care.
8 Nov, 2022 | 12:37h | UTCNews Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal
Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.
8 Nov, 2022 | 12:30h | UTCSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD. #AHA22 https://t.co/eLgnrnTm5D pic.twitter.com/QmNUcxeJwX
— NEJM (@NEJM) November 6, 2022
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022
Guidance for the diagnosis and treatment of hypolipidemia disorders.
28 Oct, 2022 | 13:19h | UTCGuidance for the diagnosis and treatment of hypolipidemia disorders – Journal of Clinical Lipidology
Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.
20 Oct, 2022 | 12:25h | UTC
Cross-sectional study | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
20 Oct, 2022 | 12:22h | UTC
Commentary on Twitter
The Lp(a) Heritage study, in prep for Lp(a) HORIZON, is now out- 48,129 pts eligible otherwise for Lp(a) HORIZON, with survey of Lp(a) levels. Data shows a higher prevalence of ⏫levels in pts with ASCVD vs general population at >70 mg/dL/>150 nmol/L https://t.co/lcp0gSLhCJ pic.twitter.com/DBGBNk0SOa
— Sam Tsimikas, MD (@Lpa_Doc) October 18, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.
19 Oct, 2022 | 14:15h | UTC
Perspective | The polypill: from concept and evidence to implementation.
18 Oct, 2022 | 12:55h | UTCThe polypill: from concept and evidence to implementation – The Lancet (free registration required)
Related:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.
11 Oct, 2022 | 13:29h | UTCSee also: DIAL Model Calculator
Cohort Study | Association between dairy intake and risk of CV disease and mortality in patients with stable angina pectoris.
28 Sep, 2022 | 13:38h | UTC
Network M-A | Associations between statins and adverse events in secondary prevention of cardiovascular disease.
20 Sep, 2022 | 13:30h | UTC